Bromantane for Health & Longevity

Evidence Review created on 10/14/2026 using AI4L + evidence-mcp / Wonder 1.0

Also known as: Ladasten, Bromantan, Bromontan, ADK-709, Adamantylbromophenylamine

Motivation

Bromantane is a laboratory-made oral medication first developed in Russia for states marked by persistent weakness, low drive and poor tolerance of mental or physical load. It belongs to a Russian class of compounds studied for work capacity under strain rather than for wakefulness alone. Interest among health- and longevity-oriented adults centres on energy, motivation and tolerance of load, and on how its profile compares with familiar stimulants.

The compound emerged from Soviet work on sustaining performance under heat, low oxygen and prolonged exertion, and later entered Russian clinical practice under the name Ladasten. Its public profile widened after detection in competitive sport in the nineteen nineties, while later clinical publications from Russian centres examined persistent weakness, fatigue and related loss of capacity.

This review examines what bromantane is, how it may act in the brain, what human and animal studies have examined, and where evidence on benefits, harms, interactions, sourcing and monitoring remains thin. The focus stays on health and longevity use by adults willing to track outcomes carefully, rather than on treatment of a diagnosed condition.

Benefits - Risks - Protocol - Conclusion

This section lists high-level overviews that discuss bromantane by name in substantial depth.

Fewer than five qualifying items are listed because no other high-level overview meeting the eligibility rules was found, and the list is not padded with marginally relevant content. No directly relevant content from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine or Lifespan.io was found in the searches described in the comment above.

Grokipedia

Bromantane

Broad encyclopaedic overview covering development, chemistry, proposed dopamine-related actions, Russian clinical use, adverse effects, doping history and legal status, with references for further checking.

Examine

No Examine article on bromantane was found. Bromantane is a prescription medication in Russia Ladasten instructions for use, and Examine does not typically cover prescription medications.

ConsumerLab

No ConsumerLab article on bromantane was found. Bromantane is a prescription medication in Russia Ladasten instructions for use, and ConsumerLab does not typically cover prescription medications.

Systematic Reviews

No systematic reviews or meta-analyses for Bromantane were found on PubMed as of 10/13/2026.

Mechanism of Action

Bromantane is an adamantane derivative (a rigid cage-like carbon structure related to amantadine) whose best-supported action is increased dopamine production rather than strong blockade of dopamine removal. In rat brain, a single oral dose increased tyrosine hydroxylase gene expression and protein (tyrosine hydroxylase: the rate-limiting enzyme for dopamine synthesis), with region-specific dopamine changes Mikhaylova et al.. Earlier rat work reported increased gene expression for that enzyme and for aromatic L-amino acid decarboxylase (the enzyme converting the dopamine precursor into dopamine) Vakhitova et al., and other rat work reported changes in dopamine parameters and in serotonin and its metabolite content Kudrin et al.. Reviews additionally describe strengthened gamma-aminobutyric acid (GABA; the main calming brain messenger) signalling through reduced expression of a GABA transporter gene, which may contribute to the reported calming component Oliynyk & Oh. Competing accounts stress synthesis upregulation or early release and membrane-protective effects; human brain data are absent. Pharmacological properties reported in that review include incomplete oral absorption, distribution into brain lipids and adipose tissue (body fat), hepatic metabolism mainly by hydroxylation at the sixth position of the adamantane ring with stimulation of cytochrome P450 (a liver enzyme family that breaks down medicines), and urinary metabolites detectable for two weeks. Peak concentration occurred at 2.75 hours in women and 4.0 hours in men; precise half-life and receptor selectivity remain unestablished in indexed human studies. Reproduced Russian product information gives a half-life near eleven hours Ladasten instructions for use.

Historical Context & Evolution

Bromantane emerged from Soviet actoprotector research in the nineteen seventies and nineteen eighties, a programme seeking compounds that sustained physical and operator work under hypoxia (low oxygen), heat and exhaustive load without the oxygen cost and heat production of classic stimulants Oliynyk & Oh. Adamantane chemistry offered a path distinct from amphetamine-like agents, and animal studies reported increased work capacity and heat resistance, alongside altered learning and immune measures. Reports from that era describe military interest in faster recovery after strong exertion, although much primary documentation remains Russian-language, incompletely indexed or unavailable in full. After the Soviet period, production continued in Russia as Ladasten, certified there as a medication Oliynyk & Oh and later studied openly in asthenia (persistent weakness and fatigue) and neurasthenia (a diagnosis centred on exhaustion, irritability and poor concentration). International attention arrived through sport: a 1997 letter described bromantan as a new doping agent after detections at the Atlanta Olympic Games Burnat et al., and anti-doping rules subsequently prohibited it. Health-optimisation interest followed from the same features that drew military and sporting interest — sustained capacity under strain, a calming alongside stimulating description, and claims of little hyperstimulation — while independent replication outside Russia has remained scarce, leaving the historical claims and the later clinical reports to be weighed on their own methods rather than on origin alone.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the human evidence consists of one small blinded comparison and open Russian clinical series, not replicated trials from independent research groups.

Medium 🟩 🟩

A randomised blind comparison with placebo (an inactive look-alike treatment) over twenty-eight days in neurasthenia reported faster and greater reduction of core asthenic symptoms with ladasten Neznamov et al.. A separate open multicentre series in asthenia with psychoautonomic syndrome (physical symptoms linked to autonomic nervous system imbalance) reported benefit from day three, persisting one month after stopping Voznesenskaia et al.. The proposed mechanism is increased dopamine synthesis. Populations were patients, not healthy longevity-oriented adults.

Magnitude: 76.0% responders on one global severity scale and 90.8% on a global improvement scale in the open multicentre series, no control group. The blinded comparison reports superiority over placebo without an abstracted numeric difference.

Reduced anxiety alongside stimulation in asthenic disorders

Russian clinical reports describe combined stimulating and anxiety-reducing actions as central to the profile in psychogenic asthenia (asthenia arising after psychological stress) and neurasthenia Siuniakov et al.. The blinded placebo comparison by Neznamov and colleagues drew the same conclusion Neznamov et al.. The proposed calming mechanism is strengthened gamma-aminobutyric acid signalling alongside increased dopamine synthesis. Evidence comes from one research network, in diagnosed patients, over four weeks.

Magnitude: Anxiety-reducing effects were reported during twenty-eight days in asthenic disorders; the indexed literature reports no between-group outcome figure.

Low 🟩

Psychophysiological performance during mental fatigue ⚠️ Conflicted

During fatigue, 100 milligrams once improved psychophysiological measures in volunteers, especially stress-labile individuals (easily stress-impaired) Bogdan et al.. Proposed mechanism is increased dopamine synthesis. In untired men, a placebo comparison left principal performance components unchanged, although tremor (involuntary shaking) fell Viatleva et al., so benefit may depend on fatigue state.

Magnitude: Psychophysiological measures improved during fatigue after 100 milligrams, while principal performance components were unchanged in untired men; the indexed literature reports no outcome figure.

Work capacity and heat resistance under extreme load

Animal studies report greater work capacity and heat and low-oxygen resistance Oliynyk & Oh. Proposed mechanisms are increased dopamine synthesis and membrane protection. In volunteers, 250 milligrams once improved stability under heat plus carbon monoxide versus placebo Sedov et al.. Heat stability is not endurance; transfer is indirect.

Magnitude: Stability under combined heat and carbon monoxide exposure was greater with 250 milligrams than with placebo in volunteers; the indexed literature reports no outcome figure.

Speculative 🟨

Learning and memory processes

Rat studies report strengthened hippocampal long-term potentiation (strengthening of connections between brain cells) with ladasten Mikhaylova et al.. No human learning or memory outcome is reported; basis is animal only.

Immune modulation under stress

A mouse study reports changes in T-lymphocyte subsets (immune cells coordinating defence) under stress models, without human immune outcomes Tallerova et al.. The basis is animal only.

Longevity or healthspan extension

No study has measured lifespan, healthspan (years lived in good health), ageing biomarkers validated against outcomes, or age-related disease incidence with bromantane. Any longevity claim rests on indirect inference from fatigue and dopamine findings only.

Benefit-Modifying Factors

  • Genetic variation: No human pharmacogenetic study (a study of gene effects on drug response) exists; variation in dopamine synthesis or breakdown remains a theoretical modifier only.
  • Baseline biomarkers and state: No blood biomarker predicts benefit. Reduced electroencephalogram (EEG; brain electrical activity recording) alpha activity, combined with emotional lability (rapidly shifting emotions) and inertness, characterised neurasthenia patients giving stronger subjective estimations of ladasten and placebo response Neznamov et al..
  • Sex differences: Absorption was faster in women than men in review-reported pharmacokinetic data Oliynyk & Oh, with earlier peak concentration; no sex-specific efficacy comparison in humans was found.
  • Pre-existing conditions: Studied benefit is confined to asthenia and neurasthenia; response in healthy adults, depression, or attention disorders has not been established in indexed trials.
  • Age: No indexed study focuses on older adults at the upper end of the longevity-oriented range; age effects on benefit are unknown.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: human safety data come from one small blinded comparison and open short-term series, not replicated controlled safety studies from independent groups.

Medium 🟥 🟥

No risk reaches Medium: the only quantified human safety data are uncontrolled open series, and the one blinded comparison reports no adverse-event rate in its indexed abstract.

Low 🟥

Treatment discontinuation during short-term clinical use

Voznesenskaia and colleagues’ open multicentre series, at fifty to one hundred milligrams daily for twenty-eight days, recorded uncommon treatment discontinuation and no serious adverse effects Voznesenskaia et al.. The blinded comparison by Neznamov and colleagues reports no discontinuation rate Neznamov et al.. Follow-up beyond one month is absent.

Magnitude: Therapy was discontinued in 0.8% of patients in the open multicentre series, no control group, where adverse effects occurred in 3%; no placebo-group discontinuation rate is given in the blinded comparison abstract.

Excessive activation and disturbed sleep

Activation extends the dopamine-raising profile, and Russian product descriptions list excessive activation and sleep disturbance Ladasten instructions for use, while indexed abstracts do not enumerate individual events. Asthenic patients in the open series reported normalised sleep overall Voznesenskaia et al., suggesting dependence on baseline and timing.

Magnitude: Excessive activation and sleep disturbance may occur during use, with baseline state and administration timing affecting sleep; the indexed literature reports no itemised outcome figure or comparison-group rate for activation or insomnia (difficulty falling or staying asleep).

Allergic reaction

Russian product descriptions note allergic reactions (immune responses such as rash or swelling) in individuals with heightened sensitivity Ladasten instructions for use, a class of event possible with any oral medication. The actoprotector review likewise gives no frequency or severity for such reactions to bromantane Oliynyk & Oh.

Magnitude: Allergic reactions may occur in individuals with heightened sensitivity; the indexed literature reports no outcome figure or comparison-group rate.

Speculative 🟨

Dependence or long-term dopamine adaptation

No withdrawal syndrome (symptoms after abrupt stopping) appeared after twenty-eight days in the blinded comparison Neznamov et al.. Effects of months of dopamine-synthesis upregulation in humans are unstudied; long-term adaptation remains mechanistic uncertainty only.

High-dose neurological and bodily toxicity

In rats, doses above six hundred milligrams per kilogram suppressed behaviour and altered pain responses, far above human doses by weight Iezhitsa et al.. No indexed human overdose series exists; basis is animal only.

Reproductive and developmental effects

Rat studies before mating reported altered litter size and pup survival at some doses, without consistent malformations Iezhitsa et al.. No human pregnancy data exist; basis is animal only.

Risk-Modifying Factors

  • Genetic variation: No human gene–risk study exists; inherited differences in dopamine breakdown or liver metabolism are untested theoretical modifiers.
  • Baseline markers: No baseline blood marker has been linked to bromantane harm in humans; liver health is relevant in principle because metabolism is hepatic.
  • Sex differences: Faster absorption in women is reported in review pharmacokinetic data Oliynyk & Oh; no sex-specific adverse-event comparison was found.
  • Pre-existing conditions: Mania (abnormally elevated mood and energy), psychosis (loss of contact with reality), severe anxiety, insomnia and cardiovascular disease are theoretical vulnerability states for a stimulating compound, untested in trials.
  • Age: Older adults are unstudied; slower clearance, drug burden and sleep fragility make extrapolation from younger patient series uncertain.

Key Interactions & Contraindications

  • Monoamine oxidase inhibitors (antidepressants blocking dopamine breakdown; phenelzine, tranylcypromine, selegiline): Avoid (theoretical); additive dopamine increase could produce agitation, raised blood pressure or mania (abnormally elevated mood and energy).
  • Prescription stimulants (methylphenidate, amphetamine salts, modafinil): Caution (theoretical); additive stimulation could increase insomnia, anxiety, heart rate and blood pressure. Combined use has no human study.
  • Dopamine-blocking antipsychotic medications (haloperidol, risperidone, olanzapine): Caution (theoretical); opposing dopamine actions could blunt either effect or destabilise the treated condition.
  • Levodopa and dopamine agonists (medications replacing or mimicking dopamine; pramipexole, ropinirole): Caution (theoretical); additive dopamine could increase dyskinesia (involuntary movements), agitation or hallucinations (perceiving absent things).
  • Serotonergic antidepressants (antidepressants acting on serotonin, a brain messenger involved in mood and sleep; sertraline, fluoxetine, venlafaxine): Monitor (theoretical); bromantane altered serotonin measures in rat brain, so additive agitation or sleep disturbance is possible, unquantified in humans.
  • Benzodiazepines and sedating medications (calming or sleep medications; lorazepam, zolpidem): Monitor (theoretical); product information reports reduced hypnotic effect of thiopental (a barbiturate anaesthetic) but no weakening of benzodiazepine anxiety reduction Ladasten instructions for use, while other sedative combinations remain unstudied in humans.
  • Medications cleared by cytochrome P450 liver enzymes (simvastatin, amlodipine, sertraline): Monitor (theoretical); review-reported stimulation of cytochrome P450 could lower exposure and reduce efficacy, with no human magnitude known.
  • Over-the-counter stimulants and decongestants (caffeine products, pseudoephedrine): Caution (theoretical); additive activation could worsen insomnia, tremor (involuntary shaking), palpitations (awareness of forceful heartbeat) or raised blood pressure.
  • Supplements raising dopamine or stimulation (L-tyrosine, mucuna, high-dose caffeine, yohimbine): Caution (theoretical); additive precursor supply or stimulation could increase agitation and sleep loss. No combination study exists.

Populations who should avoid Bromantane:

  • Pregnancy and breastfeeding, reflecting absent human data and animal reproductive findings.
  • Children and adolescents up to 18 years, the limit given in reproduced Ladasten instructions for use Ladasten instructions for use.
  • Athletes subject to anti-doping testing, because bromantan is listed among prohibited stimulants on the World Anti-Doping Agency Prohibited List The Prohibited List.
  • Current mania or psychosis (theoretical), because dopamine-raising stimulation could aggravate either state.
  • Known hypersensitivity (immune over-reaction) to bromantane or its formulation components.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Morning administration: Russian product descriptions place the last dose before late afternoon, limiting sleep disturbance from residual activation.
  • Lowest studied range first: Clinical series used fifty to one hundred milligrams daily for twenty-eight days Voznesenskaia et al., limiting dose-related activation.
  • Time-limited course: Studied courses lasted twenty-eight days Neznamov et al., limiting unknown long-term dopamine adaptation.
  • Stimulant separation: Other stimulants are held or reduced during initial use, limiting additive insomnia, anxiety and cardiovascular activation.
  • Sleep and mood tracking: Daily sleep, agitation and mood-elevation records detect excessive activation early, before escalation into severe insomnia or mania.
  • Tested-athlete exclusion: Anti-doping status is checked before any use, preventing a prohibited-stimulant violation The Prohibited List, with urinary metabolites reported detectable for two weeks Oliynyk & Oh.

Therapeutic Protocol

Other parameters without a citation below reflect common practice.

  • Studied daily dose: Fifty to one hundred milligrams daily for twenty-eight days in the open multicentre asthenia series Voznesenskaia et al..
  • Blinded-comparison regimen: Twenty-eight days of ladasten monotherapy followed by one week of placebo in neurasthenia Neznamov et al.; the indexed abstract omits the dose.
  • Single-dose volunteer study: One hundred milligrams once in healthy volunteers under mental-fatigue testing Bogdan et al..
  • Time of day: Morning administration, with Russian product descriptions placing the final dose before late afternoon because of activation and sleep effects Ladasten instructions for use.
  • Single or split dose: Russian product descriptions distribute one hundred to two hundred milligrams across two daytime doses Ladasten instructions for use, while the cited clinical series reports only the daily total.
  • Half-life: Reproduced Russian product information gives approximately eleven hours Ladasten instructions for use; no indexed primary human study verifies the figure, and metabolites persist longer.
  • Genetic variation: No gene-guided dosing exists; catechol-O-methyltransferase (COMT; an enzyme breaking down dopamine) variation is discussed only as an untested theoretical modifier.
  • Sex differences: Peak concentration occurred earlier in women than men in review data Oliynyk & Oh; no sex-specific dose is established.
  • Age: No older-adult protocol exists; studied populations were predominantly working-age patients with asthenic disorders.
  • Baseline biomarkers and state: No baseline biomarker level guides dose choice; protocols originate in asthenia and neurasthenia, so use in rested healthy adults extrapolates beyond the studied baseline.
  • Pre-existing conditions: Liver disease, mania, psychosis, severe insomnia and stimulant sensitivity have no studied protocol and remain exclusionary in cautious practice descriptions.

Discontinuation & Cycling

  • Duration: Studied use is a short course of twenty-eight days, not lifelong administration, in the indexed Russian clinical reports.
  • Withdrawal: No withdrawal syndrome appeared during a one-week placebo period after twenty-eight days in the blinded comparison Neznamov et al..
  • Persistence after stopping: The open multicentre series reported anti-asthenic effect still present one month after withdrawal of therapy Voznesenskaia et al..
  • Tapering: No tapering schedule is described in indexed reports; studied courses ended without a reported taper phase.
  • Cycling: No controlled comparison of cycling against continuous use exists; repeat-course intervals in community practice are uncited common practice.

Sourcing and Quality

  • Regulated product: Ladasten is described as certified in Russia as a medication Oliynyk & Oh; product obtained elsewhere lacks that regulatory chain.
  • Identity testing: Material sold as a research chemical carries unverified identity and purity; independent chromatographic and mass-spectrometric identity confirmation addresses substitution risk.
  • Dose uniformity: Unregulated powders and capsules vary in content; batch-specific assay (a laboratory measurement of amount present) documentation addresses dose uncertainty.
  • Reputable brands: No brand outside the Russian Ladasten product has published comparative quality data, and no compounding-pharmacy standard was found.
  • Storage: The compound is lipophilic (fat-soluble) and distributes into fat tissue; sealed, dry, light-protected storage follows general practice for such oral medications.

Practical Considerations

  • Time to effect: The open series reported anti-asthenic effect from day three of a twenty-eight-day course Voznesenskaia et al..
  • Common pitfalls: Late-day administration, combining with other stimulants, and indefinite continuation beyond studied courses are recurring errors in community reports.
  • Regulatory status: Bromantan is listed among prohibited stimulants in tested sport The Prohibited List; the regulated product identified is the Russian Ladasten product Ladasten instructions for use.
  • Cost and access: Access outside Russia depends on unregulated research-chemical vendors, with variable price and no assured pharmaceutical quality.
  • Detection window: Urinary metabolites were reported detectable two weeks after administration Oliynyk & Oh, outlasting perceived effects.

Interaction with Foundational Habits

  • Sleep: Direct and potentially blunting; dopamine-raising activation can delay sleep when administered late, while asthenic patients reported normalised sleep overall. Morning timing is the practical variable.
  • Nutrition: Indirect; no nutrient depletion or required diet is documented. Oral absorption is incomplete and the compound is fat-soluble, so administration relative to meals may alter uptake, untested in humans.
  • Exercise: Potentially potentiating in animal work-capacity models through dopamine synthesis and actoprotector mechanisms, with no controlled human training study; human evidence is limited to a heat-stress volunteer study, without a training outcome.
  • Stress management: Indirect and potentially potentiating through increased dopamine synthesis and strengthened calming-messenger signalling; healthy-volunteer effects were larger in stress-labile individuals, and anxiety reduction accompanied stimulation in patient series, without cortisol (a stress hormone) outcome data.

Monitoring Protocol & Defining Success

Baseline assessment before any course captures resting blood pressure and heart rate on three separate mornings, a two-week sleep and energy record, current stimulant and medication use, and liver blood testing where hepatic risk (liver-related risk) exists. Personal baselines matter because no bromantane-specific laboratory target exists, and the studied populations were patients rather than healthy adults. Ongoing monitoring repeats blood pressure, heart rate and sleep records at one week and four weeks, with liver testing repeated at four weeks when baseline values or symptoms warrant it. Success is defined against the individual baseline record, not against population averages, and each course is judged against that same personal record over time.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Systolic and diastolic blood pressure No established target — track change from the individual baseline Safety check for cardiovascular activation Seated, morning, before caffeine or exercise; same arm and cuff size each time
Resting heart rate 60–100 beats per minute (standard reference range) Safety check for cardiovascular activation On waking, before rising; paired with blood pressure and sleep record; track change from the individual baseline
Alanine aminotransferase 7–56 units per litre (standard reference range) Safety check during hepatic metabolism A liver enzyme released when liver cells are injured; fasting not required; laboratory ranges vary by sex and method

Qualitative markers tracked alongside measurements:

  • Sleep onset, awakenings and morning restoration
  • Daytime energy and motivation across the working day
  • Anxiety, irritability and any elevation of mood or speech pressure
  • Sustained work capacity under mental fatigue

Emerging Research

  • Registered trials: A ClinicalTrials.gov search on 13 October 2026 returned no study for bromantane; consequently no registered trial currently tests a benefit or risk claim in this review.
  • Independent replication: A blinded trial outside Russia in healthy fatigued adults, extending the design of Neznamov et al., 2009, could strengthen the case if positive or weaken it if null.
  • Human pharmacokinetics: A primary human absorption and metabolism study could confirm or revise the secondary half-life figure and the sex difference summarised by Oliynyk & Oh, 2012.
  • Brain plasticity claims: Rat hippocampal findings from Mikhaylova et al., 2007 await human learning outcomes; a null human cognition trial would confine those findings to animal models.
  • Long-term safety: Treatment beyond twenty-eight days and follow-up beyond one month after stopping, absent from Voznesenskaia et al., 2010, could reveal late sleep, mood or liver effects that short courses cannot exclude.

Conclusion

Bromantane presents as a Russian oral medication with an unusual combined description: stimulating and calming at once, developed for sustained capacity under strain and later used for persistent weakness and exhaustion. The human record behind that description is narrow. One small blinded comparison and larger open Russian series in diagnosed patients form the core, supported by a single-dose volunteer study and a deep animal literature on dopamine production, work under load and immune measures. For adults focused on health and longevity, the central outcomes of interest — steadier energy, motivation and tolerance of demanding days — rest largely on transfer from patient populations, because studies in healthy people are few and studies of ageing itself are absent. Harms in short courses appear uncommon and non-serious in the published series, with activation and sleep disturbance the most plausible concerns, while long courses, older age, pregnancy, combined stimulant use and many common medicines remain essentially unstudied. Practical weight also comes from context: a prohibited status in tested sport, absence of a regulated product outside Russia, and research-chemical sourcing of uncertain purity. The evidence base is single-country and largely single-network, without independent confirmation, and that limits how far its findings travel. Interest in bromantane is understandable from its history and mechanism, yet the distance between those foundations and demonstrated benefit for healthy longevity remains wide and plainly visible in the record.

Top - Benefits - Risks - Protocol